NPC 567
Alternative Names: NOVA 567Latest Information Update: 18 Aug 1995
At a glance
- Originator Scios
- Developer GlaxoSmithKline; Scios
- Class Antiasthmatics; Kinins; Neuropeptides; Oligopeptides
- Mechanism of Action Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 18 Aug 1995 Discontinued-II for Asthma in United Kingdom (Intranasal)
- 18 Aug 1995 Discontinued-II for Asthma in USA (Intranasal)
- 18 Aug 1995 Discontinued-II for Burns in United Kingdom (Topical)